scholarly journals Serum Cytokeratin 18 as a Metastatic and Therapeutic Marker for Extramammary Paget’s Disease

Author(s):  
Mariko Urano-Takaoka ◽  
Hayakazu Sumida ◽  
Takuya Miyagawa ◽  
Kentaro Awaji ◽  
Kojiro Nagai ◽  
...  

Extramammary Paget’s disease (EMPD) is a rare cutaneous adenocarcinoma with unfavorable prognosis once it becomes invasive. A tumor marker that reflects disease progression is required for adequate management of this disease. Cytokeratin 18 is highly expressed in many types of cancer and its soluble forms are detected by M30 (for caspase-cleaved form) and M65 (for both caspase-cleaved and intact forms) assays. Here, we report that tumor cells of EMPD in both lesional skin and lymph node metastasis are positive for CK18 immunohistochemically and the baseline serum M30 and M65 levels in metastatic EMPD patients are significantly higher than those in non-metastatic patients. In addition, serial serum M30 and M65 levels might reflect recurrence of EMPD and response to chemotherapy. These results suggest that serum CK18 levels may be a useful tumor marker for advanced EMPD.

2017 ◽  
Vol 44 (6) ◽  
pp. 666-670 ◽  
Author(s):  
Junji Kato ◽  
Yasuyuki Sumikawa ◽  
Tokimasa Hida ◽  
Takafumi Kamiya ◽  
Kohei Horimoto ◽  
...  

1984 ◽  
Vol 46 (5) ◽  
pp. 1118-1122 ◽  
Author(s):  
Yoshihisa FUJII ◽  
Nobuyuki SHIRAISHI ◽  
Etsuji MATSUNAGA ◽  
Susumu TAKAYASU ◽  
Toshitaka NAKAMURA

2007 ◽  
Vol 69 (3) ◽  
pp. 273-276
Author(s):  
Satoko KUMAZAWA ◽  
Kou DAN ◽  
Teiichi MASUDA ◽  
Kazunori URABE ◽  
Masutaka FURUE

2021 ◽  
Vol 41 (1) ◽  
pp. 219-226
Author(s):  
AYA KAWAGUCHI ◽  
JUN AKIBA ◽  
REIICHIRO KONDO ◽  
EIJI SADASHIMA ◽  
SACHIKO OGASAWARA ◽  
...  

Author(s):  
J. S. Anjana ◽  
P. Rema ◽  
S. Suchetha ◽  
J. Siva Ranjith ◽  
Amrita B. Rao ◽  
...  

Diagnostics ◽  
2021 ◽  
Vol 11 (6) ◽  
pp. 1086
Author(s):  
Shun Ohmori ◽  
Yu Sawada ◽  
Natsuko Saito-Sasaki ◽  
Sayaka Sato ◽  
Yoko Minokawa ◽  
...  

Extramammary Paget’s disease is recognized as an apocrine-origin cutaneous tumor and is localized in the intraepithelial skin lesion. However, its advanced form is intractable, and there is currently no therapeutic option with a satisfactory level of clinical outcome. Therefore, it is of great importance to identify a potential biomarker to estimate tumor advancement in extramammary Paget’s disease. Dermcidin is an antimicrobial peptide derived from the eccrine gland and is identified as a biomarker in various malignancies. To investigate the potential of dermcidin in extramammary Paget’s disease, we investigated dermcidin expression in tumors using the immunostaining technique. Although previous studies have reported that extramammary Paget’s disease has no positive staining against dermcidin, 14 out of 60 patients showed positive staining of dermcidin in our study. To clarify the characteristics of positive dermcidin in extramammary Paget’s disease, we investigated the clinical characteristics of positive dermcidin extramammary Paget’s disease patients. Positive dermcidin patients showed a significantly high frequency of lymph node metastasis. We next investigated the impact of positive dermcidin on overall survival. Univariate analysis identified that positive dermcidin showed a significantly increased hazard ratio in overall survival, suggesting that dermcidin might be a prognostic factor for extramammary Paget’s disease.


Sign in / Sign up

Export Citation Format

Share Document